Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

摘要: OBJECTIVE Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety increase follicle-stimulating hormone (FSH) patients. We compared symptoms FSH levels who received conventional tamoxifen alone combination treatment goserelin, a gonadotropin-releasing (GnRH) analogue, with tamoxifen. METHODS Sixty-four premenopausal women receptor-positive early-stage cancer were included assigned randomly receive either goserelin or for 12 months. The participants evaluated blindly using the Hamilton Depression Anxiety Rating Scale, Beck Albany Panic Phobia Questionnaire (APPQ). Blood assessed at baseline, 6 RESULTS A significant time×group difference was detected in agoraphobia trends subscale APPQ levels. group showed significantly less increases greater decreases level than those tamoxifen-alone from baseline months treatment. No differences age, tumor grade, body mass index, family history found between two groups. CONCLUSION Our results suggest that resulted associated suppression goserelin.